Cyclopentolate: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: January 16, 2026

Cyclopentolate

Anticholinergics

GB MHRA

Drug class: Anticholinergics
Availability: See label
Markets covered: 1
Products on record: 4

S01FAAnticholinergics

Overview

Cyclopentolate is an active pharmaceutical ingredient in the Anticholinergics group (S01FA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	4	January 16, 2026

GBUnited Kingdom· MHRA

4 products

Uses

GBOfficial regulatory label· revised January 16, 2026[1]

As a topical mydriatic and cycloplegic.

How to take

GBOfficial regulatory label

Drug interactions

Known interactions involving Cyclopentolate. Select one for details. This list is informational and not a complete interaction checker.

Acetylcholine Bethanechol Carbamoylcholine Cevimeline Demecarium Donepezil Galantamine Isoflurophate Phenylephrine Physostigmine Pilocarpine Rivastigmine Tacrine

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL034680071 · revised January 16, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised January 16, 2026[1]

Adverse reactions are listed in the table in frequency categories under MedDRA system/organ classes.
The frequency of adverse reactions is defined using the following convention:
Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). System organ class Adverse reaction Eye disorders Not known Eye irritation, accommodation disorder, eye pain, ocular hyperaemia, vision blurred, increased intraocular pressure, conjunctivitis Gastrointestinal disorders Not known Abdominal distension a, constipation, dry mouth, nausea, vomiting, necrotising colitis b Immune system disorders Rare Allergic reaction Not known Hypersensitivity (both local and systemic hypersensitivity reactions) Nervous system disorders Not known Gait disturbance, dizziness, convulsions c, seizures c, cerebellar dysfunction, somnolence Psychiatric disorders Not known Hallucination, abnormal behaviour d, psychotic disorder d, Cardiac disorders Not known Arrhythmia, bradycardia, cardiopulmonary failure d, palpitations, tachycardia Vascular disorders Not known Flushing Skin and subcutaneous tissue disorders Not known Dry skin, rash d Renal and urinary disorders Not known Urinary retention a.
Cases of abdominal distension have been reported in infants. b. Necrotising colitis has been reported in preterm infants. c. Convulsions and seizures have been reported in children. d. Abnormal behaviour, psychotic disorders, cardiopulmonary failure and rash have been reported in the paediatric population.
5% solution than following instillation of 1% solution. Children are, however, more susceptible to such reactions than adults. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised January 16, 2026[1]

g. tachycardias, heart failure). Caution should be observed when cyclopentolate is administered to patients with epilepsy, ataxia, dementia, rhinitis sicca, gastrointestinal obstruction, toxic megacolon, myasthenia gravis, and obstructive urinary tract disorders.
1). Caution is also advised in hyperaemia as increased systemic absorption may occur. Systemic absorption may be reduced by compressing the lacrimal sac at the medial canthus for a minute during and following the instillation of the drops.
(This blocks the passage of the drops via the naso lacrimal duct to the wide absorptive area of the nasal and pharyngeal mucosa. It is especially advisable in children). Caution is advised in case of open-angle glaucoma. 3). Paediatric population Extreme caution is advised for use in individuals susceptible to belladonna alkaloids because of the increased risk of systemic toxicity.
Atropine-like effects have been reported as side effects. The product should be used with caution in infants under the age of 1 year due to the increased risk of systemic toxicity. Consider withholding feeding for four (4) hours after examination.
Observe infants closely for at least 30 minutes. 8). 8). Early symptoms may include, but are not limited to, bradycardia, vomiting, food intolerance, increased stomach residues, abdominal distension, and bloody stools. In such a case, immediate medical evaluation is needed.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drug interactions

Drugs in the same class

Sources & citations